Merck & Co Stock

Merck & Co Equity Ratio

The Equity Ratio of Merck & Co (MRK) as of Aug 7, 2026 is 38.44 %. In the previous year, Equity Ratio was 39.55 % — a change of -2.81% (lower).

Equity Ratio

38.44 %

YoY

-2.81%

Last updated:

Equity Ratio of Merck & Co is 2026 38.44 % . Equity Ratio of Merck & Co was 2025 39.55 % . It decreases by -2.81% lower compared to the previous year.
Access this data via the Eulerpool API

Merck & Co Stock analysis

What does Merck & Co do? The company Merck & Co Inc has a long history. It was founded in 1891 by the German pharmacist Friedrich Jacob Merck and is now based in Kenilworth, New Jersey, USA. The company has evolved over time into a globally operating company in the pharmaceutical and chemical industry. Merck & Co Inc's business model is based on the development, production, and marketing of medicines and products for the healthcare industry. The company collaborates with other partners such as universities, other companies, and governments to achieve the best possible scientific progress. Research and development play a very important role in this. Merck is divided into three main areas: The Human Health division, which specializes in the development of prescription drugs and products to improve human health. The second division is Animal Health, which focuses on animal medicines and care products. The third division, Life Science (formerly MilliporeSigma), is dedicated to the development of products and services for biopharmaceutical research and production to facilitate the discovery and manufacturing of medicines. Merck & Co Inc. offers a wide range of products, ranging from prescription medicines to specialty chemicals. Some of the most well-known drugs include Januvia for the treatment of type 2 diabetes and Keytruda, an immuno-oncology drug used in the treatment of various types of cancer. Other well-known drugs from Merck & Co Inc. include Gardasil for the prevention of HPV infections, Propecia for the treatment of male pattern hair loss, and Zetia for the treatment of high cholesterol. The company is extremely innovative and has made significant advances in pharmaceutical research in recent decades. Merck & Co Inc. has won numerous awards over the years, including the "2018 Australian Financial Review Boss Most Innovative Companies Award" and the "2018 Global Energy Award for Technology Innovation". Merck & Co Inc. operates worldwide and has subsidiaries and partnerships in many countries. The company has about 69,000 employees and distributes its products in over 140 countries. Merck & Co Inc.'s products are typically prescription-only and prescribed by doctors and professionals. Overall, Merck & Co Inc. is a company with an impressive history that is now one of the leading companies in the pharmaceutical and chemical industry. Thanks to its innovation and its consistent focus on the needs of patients and healthcare professionals, it is able to successfully meet challenges in the healthcare industry and set new standards. Merck & Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Merck & Co stock

Equity Ratio of Merck & Co is 38.44 % in 2026.

Equity Ratio of Merck & Co changed from 39.55 % to 38.44 %, representing a -2.81% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio Merck & Co since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's Merck & Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — Merck & Co

All Key Metrics — Merck & Co